New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

Barchart · 2d ago

DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The analysis showed that highly adherent participants who remained on icosapent ethyl (IPE) treatment for at least 1.5 years experienced approximately 30% relative risk reduction in major adverse cardiovascular events. Additionally, secondary prevention participants who stopped IPE treatment prematurely after a mean of 2.3 years exhibited a “legacy” effect with no apparent diminution in the hazard ratio (HR) difference over the next one to four years.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.